Business
Board change
Futura Medical plc announces a board change with Harmesh Suniara stepping down as Non-Executive Director with immediate effect, following resolutions for a placing and subscription that will significantly reduce Lombard Odier Asset Management's shareholding. The company expresses gratitude for his guidance, particularly ahead of the fundraise which provides a secure financial footing. Futura Medical is now focused on completing its strategic review in Q1 FY26 and progressing the development of Eroxon Intense and WSD4000. Disclaimer*
About this update from Futura Medical Plc
[{"type":"text","content":"\n\n03 December 2025\nFutura Medical plc\n(\"Futura\", \"the Group\" or the \"Company\")\nBoard change\n \nFutura Medical (AIM:FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that following the passing of resolutions in respect to the recently announced placing and subscription, and significant reduction in Lombard Odier Asset Management's percentage shareholding in Futura following the upcoming admission of the placing shares and subscription shares to trading on AIM, Harmesh Suniara is stepping down from his role as Non-Executive Director and will step off the Board with immediate effect. Harmesh was appointed to the Board as Lombard Odier Asset Management's representative in March 2025.\n \nAndrew Unitt, Non-Executive Chair, commented: \"The Board would like to express our gratitude to Harmesh for his dedication to the Company during his tenure as Non-Executive Director; his advice and guidance have been invaluable ahead of the completion of the fundraise. With the successful fundraising in place giving the Company a sure financial footing, we are now focused on the competition of the strategic review in Q1 FY26, alongside progressing the development of Eroxon Intense and WSD4000.\"\n \nContacts:\n\n\n\n\nFutura Medical plc\n \n \n \n\n\nAlex Duggan\nChief Executive Officer\nAngela Hildreth\nFinance Director and COO\n \n\n\[email protected]\n+44 (0)1483 685 670\nwww.futuramedical.com\n \n\n\n\n\nPanmure Liberum\nNominated Adviser\nand Broker\n \n\n\nEmma Earl, Will Goode, Mark Rogers (Corporate Finance)\nRupert Dearden (Corporate Broking)\n\n\n+44 (0)20 3100 2000\n \n \n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nTurner Pope Investments (TPI) Ltd\nBroker\n \n\n\nGuy McDougall / Andrew Thacker\n\n\n+44 (0) 20 3657 0050\n \n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nAlma Strategic Communications\n\n\nRebecca Sanders-Hewett\nSam Modlin\nEmma Thompson\n\n\n+44 (0)20 3405 0205\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nNotes to Editors:\n \nFutura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and development products WSD4000 and Ero...